BioAdvance had what it is calling a "record-breaking year" of investing in 2022, putting more than $4.7 million into eight new companies and several existing portfolio companies.
The addition of eight new companies is the Wayne-based venture investor's highest tally in 10 years.
Dr. Shahram Hejazi, BioAdvance's CEO and managing director, said the increased investment is a result of "revamped" investment strategy that has it backing very early-stage startups from a range of life sciences segments…
